DAMPening Inflammation by Modulating TLR Signalling

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2010 Aug 14

PMID 20706656

Citations 459

Authors

A M Piccinini

K S Midwood

Affiliations

Soon will be listed here.

Abstract

Damage-associated molecular patterns (DAMPs) include endogenous intracellular molecules released by activated or necrotic cells and extracellular matrix (ECM) molecules that are upregulated upon injury or degraded following tissue damage. DAMPs are vital danger signals that alert our immune system to tissue damage upon both infectious and sterile insult. DAMP activation of Toll-like receptors (TLRs) induces inflammatory gene expression to mediate tissue repair. However, DAMPs have also been implicated in diseases where excessive inflammation plays a key role in pathogenesis, including rheumatoid arthritis (RA), cancer, and atherosclerosis. TLR activation by DAMPs may initiate positive feedback loops where increasing tissue damage perpetuates pro-inflammatory responses leading to chronic inflammation. Here we explore the current knowledge about distinct signalling cascades resulting from self TLR activation. We also discuss the involvement of endogenous TLR activators in disease and highlight how specifically targeting DAMPs may yield therapies that do not globally suppress the immune system.

Citing Articles

Targeting Lung Damage: Amniotic Mesenchymal Stem Cells Mitigate Lipopolysaccharide-Induced Acute Lung Injury via Multiple Signaling Pathways.

Niu X, Zhang L, Xing S, Liu J, Li D, Wang Y Int J Mol Sci. 2025; 26(5).

PMID: 40076934 PMC: 11901019. DOI: 10.3390/ijms26052314.

The Inter-Relationships Among the Risk Factors for Pulmonary Infection and the Diagnostic Utility of Inflammatory Markers in Patients with Non-Small Cell Lung Cancer.

Qin W, You T, Guo T, Tian R, Cui X, Wang P Infect Drug Resist. 2025; 18:1111-1123.

PMID: 40027913 PMC: 11871871. DOI: 10.2147/IDR.S491507.

Understanding Host-Pathogen Interactions in Congenital Chagas Disease Through Transcriptomic Approaches.

Caceres T, Patino L, Ramirez J Pathogens. 2025; 14(2).

PMID: 40005483 PMC: 11858232. DOI: 10.3390/pathogens14020106.

Modic changes: From potential molecular mechanisms to future research directions (Review).

Zhu W, Yang Z, Zhou S, Zhang J, Xu Z, Xiong W Mol Med Rep. 2025; 31(4).

PMID: 39918002 PMC: 11836598. DOI: 10.3892/mmr.2025.13455.

Inflammatory changes in the choroid plexus following subarachnoid hemorrhage: the role of innate immune receptors and inflammatory molecules.

Solar P, Brazda V, Bares M, Zamani A, EmamiAref P, Joukal A Front Cell Neurosci. 2025; 18():1525415.

PMID: 39839349 PMC: 11747387. DOI: 10.3389/fncel.2024.1525415.

References

Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E . Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol. 2008; 29(2):180-9. DOI: 10.1007/s10875-008-9252-x. View

Mintz M, Sowers R, Brown K, Hilmer S, Mazza B, Huvos A . An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005; 65(5):1748-54. DOI: 10.1158/0008-5472.CAN-04-2463. View

Klune J, Dhupar R, Cardinal J, Billiar T, Tsung A . HMGB1: endogenous danger signaling. Mol Med. 2008; 14(7-8):476-84. PMC: 2323334. DOI: 10.2119/2008-00034.Klune. View

Youssef P, Roth J, Frosch M, Costello P, FitzGerald O, Sorg C . Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol. 1999; 26(12):2523-8. View

Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P . Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008; 103(12):1402-9. PMC: 2994199. DOI: 10.1161/CIRCRESAHA.108.178426. View

Cheng N, He R, Tian J, Ye P, Ye R . Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 2008; 181(1):22-6. PMC: 2464454. DOI: 10.4049/jimmunol.181.1.22. View

Yang D, Chen Q, Su S, Zhang P, Kurosaka K, Caspi R . Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med. 2008; 205(1):79-90. PMC: 2234357. DOI: 10.1084/jem.20062027. View

Urbonaviciute V, Furnrohr B, Meister S, Munoz L, Heyder P, De Marchis F . Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008; 205(13):3007-18. PMC: 2605236. DOI: 10.1084/jem.20081165. View

Miller Y, Viriyakosol S, Binder C, Feramisco J, Kirkland T, Witztum J . Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2002; 278(3):1561-8. DOI: 10.1074/jbc.M209634200. View

10.

Izuishi K, Tsung A, Jeyabalan G, Critchlow N, Li J, Tracey K . Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol. 2006; 176(12):7154-8. DOI: 10.4049/jimmunol.176.12.7154. View

11.

Rossignol D, Lynn M . TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs. 2005; 6(5):496-502. View

12.

Tani K, Murphy W, Chertov O, Salcedo R, Koh C, Utsunomiya I . Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol. 2000; 12(5):691-700. DOI: 10.1093/intimm/12.5.691. View

13.

Agnello D, Wang H, Yang H, Tracey K, Ghezzi P . HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine. 2002; 18(4):231-6. DOI: 10.1006/cyto.2002.0890. View

14.

Chesler E, Miller D, Branstetter L, Galloway L, Jackson B, Philip V . The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm Genome. 2008; 19(6):382-9. PMC: 2745091. DOI: 10.1007/s00335-008-9135-8. View

15.

Vabulas R, Ahmad-Nejad P, Ghose S, Kirschning C, Issels R, Wagner H . HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002; 277(17):15107-12. DOI: 10.1074/jbc.M111204200. View

16.

Devaraj S, Dasu M, Park S, Jialal I . Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009; 52(8):1665-8. PMC: 2709882. DOI: 10.1007/s00125-009-1394-8. View

17.

Ulloa L, Batliwalla F, Andersson U, Gregersen P, Tracey K . High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 2003; 48(4):876-81. DOI: 10.1002/art.10854. View

18.

Togo S, Matsuo K, Ishibe A, Nagano Y, Takahashi M, Mochizuki H . Usefulness of a selective neutrophil elastase inhibitor (sivelestat) in septic ARDS patients after gastrointestinal surgery. Hepatogastroenterology. 2008; 55(84):967-73. View

19.

OConnor K, Hansen M, Rachal Pugh C, Deak M, Biedenkapp J, Milligan E . Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effects. Cytokine. 2003; 24(6):254-65. DOI: 10.1016/j.cyto.2003.08.001. View

20.

Midwood K, Piccinini A, Sacre S . Targeting Toll-like receptors in autoimmunity. Curr Drug Targets. 2009; 10(11):1139-55. DOI: 10.2174/138945009789735101. View